507 related articles for article (PubMed ID: 21693322)
41. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
[TBL] [Abstract][Full Text] [Related]
42. Graft-versus-leukemia effect using mixed allogeneic bone marrow transplantation.
Sykes M; Bukhari Z; Sachs DH
Bone Marrow Transplant; 1989 Sep; 4(5):465-74. PubMed ID: 2790325
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic effect of CXCR3-expressing regulatory T cells on liver, lung and intestinal damages in a murine acute GVHD model.
Hasegawa H; Inoue A; Kohno M; Lei J; Miyazaki T; Yoshie O; Nose M; Yasukawa M
Gene Ther; 2008 Feb; 15(3):171-82. PubMed ID: 17989707
[TBL] [Abstract][Full Text] [Related]
44. Co-transplantation of bone marrow stromal cells transduced with IL-7 gene enhances immune reconstitution after allogeneic bone marrow transplantation in mice.
Li A; Zhang Q; Jiang J; Yuan G; Feng Y; Hao J; Li C; Gao X; Wang G; Xie S
Gene Ther; 2006 Aug; 13(15):1178-87. PubMed ID: 16598299
[TBL] [Abstract][Full Text] [Related]
45. Effects of T cell depletion in radiation bone marrow chimeras. I. Evidence for a donor cell population which increases allogeneic chimerism but which lacks the potential to produce GVHD.
Sykes M; Sheard M; Sachs DH
J Immunol; 1988 Oct; 141(7):2282-8. PubMed ID: 3049804
[TBL] [Abstract][Full Text] [Related]
46. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
47. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice.
Zeis M; Steinmann J; Petrela E; Hartung G; Schmitz N; Uharek L
Bone Marrow Transplant; 2001 Feb; 27(3):279-85. PubMed ID: 11277175
[TBL] [Abstract][Full Text] [Related]
48. Tolerance induction by third-party "off-the-shelf" CD4+CD25+ Treg cells.
Steiner D; Brunicki N; Blazar BR; Bachar-Lustig E; Reisner Y
Exp Hematol; 2006 Jan; 34(1):66-71. PubMed ID: 16413392
[TBL] [Abstract][Full Text] [Related]
49. Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host disease.
Xia G; Kovochich M; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2004 Nov; 10(11):748-60. PubMed ID: 15505606
[TBL] [Abstract][Full Text] [Related]
50. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
Azuma E; Yamamoto H; Kaplan J
J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409
[TBL] [Abstract][Full Text] [Related]
51. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
Ildstad ST; Wren SM; Bluestone JA; Barbieri SA; Stephany D; Sachs DH
J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464
[TBL] [Abstract][Full Text] [Related]
52. Achieving alloengraftment without graft-versus-host disease: approaches using mixed allogeneic bone marrow transplantation.
Sykes M; Sharabi Y; Sachs DH
Bone Marrow Transplant; 1988 Sep; 3(5):379-86. PubMed ID: 3056545
[TBL] [Abstract][Full Text] [Related]
53. Enhanced graft-versus-host disease in older recipient mice following allogeneic bone marrow transplantation.
Bryson JS; Jennings CD; Caywood BE; Dix AR; Lowery DM; Kaplan AM
Bone Marrow Transplant; 1997 Apr; 19(7):721-8. PubMed ID: 9156250
[TBL] [Abstract][Full Text] [Related]
54. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
Johnson BD; Drobyski WR; Truitt RL
Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
[TBL] [Abstract][Full Text] [Related]
55. Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo.
Zhang P; Tey SK; Koyama M; Kuns RD; Olver SD; Lineburg KE; Lor M; Teal BE; Raffelt NC; Raju J; Leveque L; Markey KA; Varelias A; Clouston AD; Lane SW; MacDonald KP; Hill GR
J Immunol; 2013 Nov; 191(10):5291-303. PubMed ID: 24123683
[TBL] [Abstract][Full Text] [Related]
56. [An absence of donor TH17 differentiation ameliorates dermal tissue damage].
Cheng H; Song GL; Pan B; Tian J; Yan ZL; Chen W; Xu KL; Li ZY; Zeng LY
Zhonghua Yi Xue Za Zhi; 2011 Jul; 91(26):1843-6. PubMed ID: 22093788
[TBL] [Abstract][Full Text] [Related]
57. IL-2-targeted therapy ameliorates the severity of graft-versus-host disease: ex vivo selective depletion of host-reactive T cells and in vivo therapy.
Yarkoni S; Prigozhina TB; Slavin S; Askenasy N
Biol Blood Marrow Transplant; 2012 Apr; 18(4):523-35. PubMed ID: 22227590
[TBL] [Abstract][Full Text] [Related]
58. Host Foxp3+CD4+ Regulatory T Cells Act as a Negative Regulator of Dendritic Cells in the Peritransplantation Period.
Inoue T; Ikegame K; Kaida K; Okada M; Yoshihara S; Tamaki H; Fujimori Y; Soma T; Ogawa H
J Immunol; 2016 Jan; 196(1):469-83. PubMed ID: 26621858
[TBL] [Abstract][Full Text] [Related]
59. Early expression of plasma CCL8 closely correlates with survival rate of acute graft-vs.-host disease in mice.
Yamamoto M; Ota A; Hori T; Imai S; Sohma H; Suzuki N; Hatakeyama N; Inazawa N; Ito YM; Kimura H; Tsutsumi H; Kokai Y
Exp Hematol; 2011 Nov; 39(11):1101-12. PubMed ID: 21782767
[TBL] [Abstract][Full Text] [Related]
60. [Experimental study on rejection of allogeneic donor bone marrow cells in sensitized recipients].
Xu LH; Fang JP; Weng WJ; Xu HG; Ye QX
Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):734-8. PubMed ID: 22339907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
